Dr. Dhakal on the Implementation of Trastuzumab Deruxtecan Across the HER2+ Breast Cancer Landscape
January 12th 2023Ajay Dhakal, MBBS, discusses the evolution and implementation of the antibody-drug conjugate trastuzumab deruxtecan across the landscape of HER2-positive breast cancer landscape.
Read More